Oncology Market Access in China - Market bolstered by rising incidence and improved regulatory environment

Introduction

The increasing adoption of Westernized lifestyles coupled with ongoing economic development is driving up the number of cancer patients in China. Increased healthcare spending and an improved regulatory environment promise to make the Chinese market more attractive for drug developers.

Features and benefits

* An analysis of the key factors for success in China in the context of the overall healthcare industry
* An evaluation of the key active companies in the Chinese cancer sector and their market entry strategies
* In-depth analysis of the opportunities and threats facing the oncology market and patient care pathwys for the individual therapies
* Analysis of the current epidemiology and market trends within the Chinese oncology market

Highlights

The Chinese oncology market will continue to grow as the number of elderly patients increases and lifestyles change as a result of urbanization. Increased healthcare spending and improved healthcare insurance coverage will further boost the consumption of cancer drugs.
While improved regulation of drug applications will accelerate market access for new oncology drugs, some regulatory issues remain potential threats. Among these are the drug pricing curb and the new tendering and bidding system.
International companies can gain improved access to the Chinese oncology market through manufacturing, marketing and distribution partnerships with local companies. Integrating China into the global drug development program will help accelerate the introduction of cancer drugs to the market.

Your key questions answered

* Understand patients care pathways in China and the key factors influencing the treatment cancer patients receive
* Identify the key international and local companies involved in the Chinese oncology market and their key oncology products
* Identify market access strategies to accelerate approval of drugs and gain maximum market penetration
[Studien Infos ausblenden]

Executive Summary
Scope of the analysis
Datamonitor insight into the Chinese oncology market
Related reports
Upcoming reports
OVERVIEW
Catalyst
Summary
CANCER EPIDEMIOLOGY IN CHINA
Background of cancer registration in China
Most common cancers in China
Cancer temporal trends in China
Cancer mortality rate trends in China
DRIVERS OF CANCER EPIDEMIOLOGY IN CHINA
Population dynamics
Ageing
Urbanization
Population in major urban centers of China
Risk factors driving cancer epidemiology in China
Dietary factors
Infectious agents
Environmental and occupational exposures
Limitations of Chinese cancer data
MARKET OVERVIEW
Key findings
Patient care pathways for the Chinese oncology market
Cancer treatment guidelines in China are largely in accordance with the international standards
Tier 3 hospitals are major channels for cancer treatment in China
Independent oncology hospitals are staffed with either highly qualified Chinese physicians who have expertise in cancer diagnosis and treatment, or foreign experts with extensive experience in world renowned cancer centers such as Memorial Sloan Kettering. These centers may provide integrated, multidisciplinary cancer care with diagnostic, medical oncology, and radiation oncology services, including anticancer agents and supportive care, all offered in one location.
Drug cost plays a key role in therapy choices
Lack of reimbursement hinders access
Emergence of private insurance may improve medical access
Patient care programs led by multinational companies can mitigate the financial burden on Chinese patients
Targeted therapy development in China
Targeted therapies have revolutionized cancer treatment
Multinational companies dominate the targeted therapy market in China but the market is far from saturated
Local companies are accelerating development steps
Cost and reimbursement issues hinder the prescription of targeted therapies
Opportunities and threats
Opportunity one: aging population in China will lead to an increase in cancer incidence
Opportunity two: increasing urbanization may lead to a rise in cancer incidence
Opportunity three: expansion of cancer registries and other improved information infrastructures will more accurately record the number of diagnosed patients
Opportunity four: fast track approval system for cancer drugs will shorten the market access lag
Opportunity five: increased healthcare spending will boost the consumption of cancer drugs
Opportunity six: improved healthcare insurance coverage will further expand the oncology market
Threat one: price cuts
Threat two: new tendering and bidding system might further squeeze drug profits
Threat three: competition in the local oncology market
KEY COMPANIES
Key findings
Multinational corporations
Roche
AstraZeneca
Sanofi
Domestic companies
Hengrui Pharma
Wanle Pharma
Deals and acquisitions
Recent deals and alliances in the oncology market in China show the high level of interest
Oncology has been an attractive therapeutic area for developers in China in recent years
Most deals in the Chinese oncology sector are concerned with the development of promising early-stage compounds
Simcere has been the most active pharmaceutical company in terms of deals
MARKET ACCESS
Key findings
Strategies for market penetration
Establishing a presence
Sales and marketing partnerships
Distribution development partnerships
Integrating China in the global drug development program accelerates the introduction of cancer drugs to the market
SWOT analysis of the Chinese oncology market
Strengths
Weaknesses
Opportunities
Threats
BIBLIOGRAPHY
Journal Papers
Websites
Other
Datamonitor reports
APPENDIX
Contributing experts
Report methodology
[Inhaltsverzeichnis ausblenden]